Therapeutic Options for Visceral Leishmaniasis

作者: Begoña Monge-Maillo , Rogelio López-Vélez

DOI: 10.1007/S40265-013-0133-0

关键词: Leishmania chagasiPentamidineLeishmania donovaniVisceral leishmaniasisPharmacotherapyImmunologyMedicineLeishmania infantumLeishmaniaVirologyLeishmaniasis

摘要: Visceral leishmaniasis (VL), also known as Kala-Azar, is a disseminated protozoal infection caused principally by Leishmania donovani and infantum (known chagasi in South America). The therapeutic options for VL are diverse depend on different factors, such the geographical area of infection, development resistance to habitual treatments, HIV co-infection, malnourishment other concomitant infections. This article provides an exhaustive review literature regarding studies published treatment VL, gives recommendations stratified according their level evidence, species implicated location infection.

参考文章(138)
Jorge Alvar, Simon Croft, Piero Olliaro, Chemotherapy in the Treatment and Control of Leishmaniasis Advances in Parasitology. ,vol. 61, pp. 223- 274 ,(2006) , 10.1016/S0065-308X(05)61006-8
Fernando Laguna, Rogelio López-Vélez, Federico Pulido, Ana Salas, Julián Torre-Cisneros, Enrique Torres, Francisco J Medrano, Jesús Sanz, Gabriela Picó, Javier Gómez-Rodrigo, Juan Pasquauk, Jorge Alvar, Spanish HIV-Leishmania Study Group, None, Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B AIDS. ,vol. 13, pp. 1063- 1069 ,(1999) , 10.1097/00002030-199906180-00009
A. Bryceson, W Peters, R. Killick-Kendrick, Therapy in man. Academic Press. pp. 847- 907 ,(1987)
C. P. Thakur, G. P. Sinha, D. Barat, R. K. Singh, A. K. Pandey, Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparison. Bulletin of The World Health Organization. ,vol. 72, pp. 931- 936 ,(1994)
A. Bryceson, L. Gradoni, P. Desjeux, Treatment of Mediterranean visceral leishmaniasis. Bulletin of The World Health Organization. ,vol. 73, pp. 191- 197 ,(1995)
S. Sundar, G Agrawal, M. Rai, M K Makharia, H. W Murray, D. N J Lockwood, Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ. ,vol. 323, pp. 419- 422 ,(2001) , 10.1136/BMJ.323.7310.419
V. Pintado, R. López-Vélez, HIV-associated visceral leishmaniasis. Clinical Microbiology and Infection. ,vol. 7, pp. 291- 300 ,(2001) , 10.1046/J.1198-743X.2001.00262.X
Jonathan D. Berman, Barbara L. Herwaldt, Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. American Journal of Tropical Medicine and Hygiene. ,vol. 46, pp. 296- 306 ,(1992) , 10.4269/AJTMH.1992.46.296
R. Badaro, K. Weerasuriya, C. P. Thakur, L. Pang, K. Behbehani, F. Kuzoe, R. Davidson, J. D. Berman, A. D. M. Bryceson, K. M. Wasunna, Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bulletin of The World Health Organization. ,vol. 76, pp. 25- 32 ,(1998)